Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Youn H. Kim et al.|The Lancet|2017Cited by 580
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for LymphomaChristopher J. Gibson, Benjamin L. Ebert, R. Coleman Lindsley et al.|Journal of Clinical Oncology|2017Cited by 468
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceElizabeth C. Townsend, Michelle A. Kelliher, Mark A. Murakami et al.|Cancer Cell|2016Cited by 304
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicityBenjamin L. Lampson, Jennifer R. Brown, Siddha Kasar et al.|Blood|2016Cited by 289
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantationPhilippe Armand, Alex F. Herrera, Yi‐Bin Chen et al.|Blood|2019Cited by 187